ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0631

Provider Assessment of Telehealth Utility During COVID-19

Catherine Howe1, Isaac Smith1, Robert Overton2, Ricardo Henao2, Nicoleta Economou-Zavlanos2, Jayanth Doss3, Megan Clowse4 and David Leverenz3, 1Duke University Hospital, Durham, NC, 2Duke Clinical Research Institute, Durham, NC, 3Duke University, Durham, NC, 4Duke University, Chapel Hill, NC

Meeting: ACR Convergence 2021

Keywords: Access to care, COVID-19, Disease Activity, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The COVID-19 pandemic forced the provision of telehealth care to rheumatology patients with a broader range of diagnoses and disease activity than previously studied. In this study we seek to understand factors that associate with providers’ perceptions of telehealth utility.

Methods: From 10/1/2020 – 1/31/2021, six providers at an academic medical center rated their telehealth visits according to perceived utility in making treatment decisions using the following Telehealth Utility Score (TUS) (1 = very low to 5 = very high). Ratings were entered immediately following each visit. ‘Low telehealth utility’ visits had a TUS between 1- 3 and ‘high telehealth utility’ visits had a TUS between 4-5. Providers also documented a provider global assessment of disease activity (0 = no activity to 10 = high activity). Data were obtained through the electronic data warehouse and manual chart review. Modified poisson regression models with robust error variance were used to assess the association between low versus high TUS and encounter diagnoses, current and prior patient-reported disease activity (RAPID3), provider global, and medication changes during the visit. Each analysis was performed unadjusted and adjusted according to age, race, insurance, and encounter mode (video/phone).

Results: A total of 481 telehealth encounters were included, of which 191 (39.7%) had a low telehealth utility score (Table 1). Patients with a diagnosis of inflammatory arthritis (IA) were more likely to have low telehealth utility compared to those with other diagnoses in unadjusted and adjusted models (aRR 0.806, 95% CI: 0.695-0.934, p=0.004). Furthermore, in patients with IA, the addition of a non-inflammatory musculoskeletal diagnosis made a telehealth encounter more likely to be of low utility in unadjusted and adjusted models (aRR 0.537, 95% CI: 0.344-0.838, p=0.006).

Higher patient and provider-reported measures of disease activity were significantly associated with low telehealth utility in unadjusted and adjusted models (Table 2), as follows: current RAPID3 (aRR 0.87, CI: p< 0.001), prior RAPID3 (aRR 0.89, p< 0.001), and provider global (aRR 0.83, 95% CI 0.79-0.87, p< 0.001).

An escalation in rheumatologic treatment was associated with low telehealth utility (aRR 0.7, p=0.015) and a de-escalation in rheumatologic treatment was associated with high telehealth utility (aRR 1.24, p=0.009), see Table 3.

Conclusion: Overall, telehealth was rated as a useful mode of care delivery for the majority of visits. A diagnosis of IA was associated with low telehealth utility, especially if a non-IA musculoskeletal diagnosis was also present, highlighting the need for in-person care for patients with active musculoskeletal symptoms. Intriguingly, higher disease activity by current and prior RAPID3 was associated with lower telehealth utility, suggesting that disease activity measures could help determine appropriateness for telehealth care. Finally, medication changes were associated with TUS, suggesting that providers feel comfortable decreasing medications during telehealth visits but prefer to escalate therapy in-person.

Table 1

Table 2

Table 3


Disclosures: C. Howe, None; I. Smith, None; R. Overton, Pfizer, 5; R. Henao, Pfizer, 5; N. Economou-Zavlanos, Pfizer, 5; J. Doss, Pfizer, 5; M. Clowse, UCB Pharma, 2, Pfizer, 5, GSK, 2, 5; D. Leverenz, Pfizer, 5.

To cite this abstract in AMA style:

Howe C, Smith I, Overton R, Henao R, Economou-Zavlanos N, Doss J, Clowse M, Leverenz D. Provider Assessment of Telehealth Utility During COVID-19 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/provider-assessment-of-telehealth-utility-during-covid-19/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/provider-assessment-of-telehealth-utility-during-covid-19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences